Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Microdose mushroom study for despair fails to launch

NCT ID NCT05227742

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study planned to test very low doses of psilocybin (the active ingredient in magic mushrooms) in adults with moderate to severe demoralization—feelings of hopelessness and meaninglessness often linked to illness or hardship. The goal was to see if these microdoses could improve mood and thinking without causing hallucinations. However, the study was withdrawn before enrolling any participants, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Started

Aug 2023

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Ability to read and write in English 2. Between 25 and 65 years old 3. Demoralization Scale-II (DS-II) score of \> 8 4. No prior hallucinogen use or it would have been 3 years since the last use of a hallucinogen 5. Availability of a friend, family member, or other form of transportation (e.g., Uber) to drive participants home after their drug administration sessions 6. In good general health as assessed by detailed medical history interview and physical examination Exclusion Criteria: 1. 24 years of age or younger; 66 years of age or older 2. Women who are pregnant (pregnancy status confirmed via urine pregnancy test) or breastfeeding 3. Current hypertension (exceeding 140 systolic and/or 90 diastolic at resting) 4. Use of methylphenidate or other medications for ADHD, benzodiazepines or other medications for anxiety (e.g., beta-blockers), tricyclic antidepressants, MAOIs, SSRIs, SNRIs or other medications for depression, lithium or other mood stabilizers, haloperidol or other antipsychotic medications, any medications or supplements with serotonin activity (e.g., St. John's Wort), or any other pharmacologic or biologic agent used to treat depression or anxiety (e.g., magnesium, cannabis) 5. Personal or family history (first or second degree relatives) of psychotic or bipolar I or II disorders 6. Any suicidal ideation of type 4 or type 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) in the 3 months prior to screening (i.e., active suicidal thought with method and intent but without a specific plan, or active suicidal thought with method, intent and plan). 7. History of head trauma, loss of consciousness, or neurological disease 8. Receiving treatment within the past 30 days for depression, anxiety, or substance use disorder 9. Participation within the past 30 days in a clinical trial for the treatment of depression, anxiety, or substance use disorder 10. Any current substance use disorder diagnosis (substance abstinence confirmed via urine drug screen) 11. History of immoderate alcohol consumption within the past 3 months per NIAAA definitions: more than 4 drinks per day or 14 drinks per week for men; more than 3 drinks per day or 7 drinks per week for women 12. Any headache disorder (i.e., migraine, tension-type headache, or cluster headache) in the past year 13. Planning to move from the Birmingham area in the next 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Demoralization are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.